Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study.

Abstract

PURPOSE:

Bmi-1 is a Polycomb group member which participates in many physiological processes as well as in a wide spectrum of cancers. The aim of this study was to investigate Bmi-1 expression in non-small cell lung cancer (NSCLC) in respect to clinicopathological features and therapeutic outcomes.

METHODS:

Immunohistochemical staining for Bmi-1 was performed on tissue microarrays (TMAs) constructed from 179 formalin-fixed and paraffin-embedded NSCLC samples (106 squamous, 58 adeno-, and 15 large cell carcinomas). Data were subject to statistical analysis by SPSS.

RESULTS:

Overall evaluation of all tumor cases showed that 20 (11.43%) were negative, 37 (21.14%) showed weak, 65 (37.14%) moderate and 57 (32.57%) strong nuclear positivity for Bmi-1. Statistical analysis of our data revealed that the expression of Bmi-1 was significantly higher in stage III (P = 10(-6)) and stage IV (P = 10(-5)) tumors compared to stages I and II tumors. The administration of adjuvant chemotherapy significantly increased DFS at stage I and II patients who did not express Bmi-1 when compared to their Bmi-1 positive counterparts (P = 0.05).

CONCLUSIONS:

Our results suggest that Bmi-1 is significantly associated with progression of NSCLC and might serve as a prognostic marker of adverse disease outcome.

• Authors: Katerina Vrzalikova, Joseph Skarda, Jiri Ehrmann, Paul G Murray, Eduard Fridman, Jury Kopolovic, Petra Knizetova, Marian Hajduch, Jiri Klein, Vitezslav Kolek, Lenka Radova, Zdenek Kolar
• Journal: Journal of cancer research and clinical oncology (J Cancer Res Clin Oncol) Vol. 134 Issue 9 Pg. 1037-42 (Sep 2008) ISSN: 0171-5216 [Print] Germany
• PMID: 18264721 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• BMI1 protein, human
• Nuclear Proteins
• Proto-Oncogene Proteins
• Repressor Proteins
• Polycomb Repressive Complex 1

Topics

• Carcinoma, Non-Small-Cell Lung (metabolism, pathology)
• Female
• Gene Expression Profiling
• Humans
• Immunohistochemistry
• Lung Neoplasms (metabolism, pathology)
• Male
• Neoplasm Staging
• Nuclear Proteins (genetics, metabolism)
• Polycomb Repressive Complex 1
• Prognosis
• Protein Array Analysis
• Proto-Oncogene Proteins (genetics, metabolism)
• Repressor Proteins (genetics, metabolism)
• Tissue Array Analysis